{"commentary":{"count":38,"free_build_floor":8,"listing_floor":3,"by_channel":{"youtube":15,"podcast":15,"x_thread":8},"note":"Indexed podcasts, YouTube videos and X posts that name this trial. A report screens them, searches for more and cites what clinicians said when it is built."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT03639948\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's public preview; the full report is still bought."},"name":"NeoPACT","nct_id":"NCT03639948","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=neopact-nct03639948. The price is fixed at order. We build the report after the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1250,"size":"standard","size_rule":"Standard: 13–40 commentary sources"},"registry":{"acronym":"NeoPACT","arms":[{"description":"Carboplatin (Area under the curve \\[AUC\\] 6 intravenously \\[IV\\]) and Docetaxel (75 milligrams per meter squared \\[mg/m2\\], IV) plus Pembrolizumab (200 milligrams \\[mg\\], IV) every 21 days for 6 cycles.\n\nPegfilgrastim 6 mg subcutaneous (SC) Day 2 of each cycle.","label":"Experimental: Carboplatin & Docetaxel plus Pembroluzimab","type":"EXPERIMENTAL"}],"collaborators":["Merck Sharp & Dohme LLC"],"completion_date":{"date":"2024-11","type":"ESTIMATED"},"conditions":["Triple-negative Breast Cancer"],"enrollment":{"count":120,"type":"ACTUAL"},"has_results":true,"interventions":[{"name":"Carboplatin","type":"DRUG"},{"name":"Docetaxel","type":"DRUG"},{"name":"Pembrolizumab","type":"DRUG"},{"name":"Pegfilgrastim","type":"DRUG"}],"last_update":"2024-04-11","lead_sponsor":"University of Kansas Medical Center","official_title":"Neoadjuvant Phase II Study of Pembrolizumab And Carboplatin Plus Docetaxel in Triple Negative Breast Cancer","overall_status":"UNKNOWN","phases":["PHASE2"],"primary_completion_date":{"date":"2022-01-27","type":"ACTUAL"},"primary_outcomes":[{"measure":"Pathological Complete Response (pCR) Rate","timeFrame":"Up to 25 weeks"}],"references":[{"citation":"Sharma P, Stecklein SR, Yoder R, Staley JM, Schwensen K, O'Dea A, Nye L, Satelli D, Crane G, Madan R, O'Neil MF, Wagner J, Larson KE, Balanoff C, Kilgore L, Phadnis MA, Godwin AK, Salgado R, Khan QJ, O'Shaughnessy J. Clinical and Biomarker Findings of Neoadjuvant Pembrolizumab and Carboplatin Plus Docetaxel in Triple-Negative Breast Cancer: NeoPACT Phase 2 Clinical Trial. JAMA Oncol. 2024 Feb 1;10(2):227-235. doi: 10.1001/jamaoncol.2023.5033.","pmid":"37991778","type":"DERIVED"}],"start_date":{"date":"2018-09-04","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Neoadjuvant Phase II Study of Pembrolizumab And Carboplatin Plus Docetaxel in Triple Negative Breast Cancer","url":"https://clinicaltrials.gov/study/NCT03639948"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"2.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/neopact-nct03639948"}